To clarify the relationships between marginal zone lymphomas (MZLs) and Waldenströ m macroglobulinemia/lymphoplasmacytic lymphomas (WM/LPLs), immunoglobulin heavy chain variable gene (IGHV) features were analyzed and the occurrence of MYD88 L265P mutations was identified in a series of 123 patients: 53 MZLs from the spleen (SMZLs), 11 from lymph nodes (NMZLs), 28 mucosa-associated lymphatic tissue (MALT) lymphomas and 31 WM/LPLs. SMZLs were characterized by overrepresentation of IGHV1-2 gene rearrangements with a canonical motif, without selection pressure and with long CDR3 segments. NMZLs had increased frequencies of IGHV3 genes. The IGHV gene was unmutated in most cases, often with long CDR3 segments. MALT lymphomas were usually associated with a mutated IGHV gene, but with the absence of selection pressure. WM/LPLs were associated with an IGHV3-23 overrepresentation and high IGHV mutation rate, with features of selection pressure and short CDR3 segments. MYD88 L265P mutations were almost restricted exclusively to WM/LPL patients. Taken all diagnoses together, all patients with MYD88 L265P mutations had an immunoglobulin M peak and almost all patients except one had bone marrow infiltration. These results demonstrate that the history of antigen exposure of the four entities studied was different and MYD88 L265P was specifically associated with WM/LPLs. WM/LPL may thus be functionally associated with constitutive nuclear factor-kB activation.
INTRODUCTION
Marginal zone B-cell lymphomas (MZLs) and Waldenströ m macroglobulinemia/lymphoplasmacytic lymphomas (WM/LPLs) are considered to derive from marginal zone and/or memory B cells. According to the last World Health Organization (WHO) 2008 lymphoma classification, three types of MZLs have been individualized: extranodal mucosa-associated lymphatic tissue (MALT) lymphomas, splenic MZLs (SMZLs) and nodal MZLs (NMZLs). Whereas MALT lymphomas, SMZLs and WM/LPLs are already well-characterized entities, NMZLs remain incompletely understood. 1, 2 These lymphomas share common clinical and immunohistological aspects with both SMZLs and WM/LPLs, leading to difficulties in differential diagnosis. 3, 4 NMZL is a rare malignant small B-cell lymphoma, accounting for 1.5-1.8% of all lymphoid neoplasms. 5 It is composed of small lymphocytes expressing CD20, CD22 and often surface immunoglobulin M (IgM) but usually negative for CD5, CD10, CD23 and cyclin D1. A monoclonal serum immunoglobulin may be observed and cryoglobulins may be present when associated with hepatitis C virus (HCV) infection. 6 Outcome is variable, with slow progression and a 5-year overall survival rate of 60-70%. 7 Patients at diagnosis often exhibit peripheral and abdominal nodal involvement with good performance status and no B symptoms. Bone marrow involvement occurs in approximately half of patients. Peripheral blood involvement and cytopenia are rare.
Even if typical MZL features are well described in the literature, 8 morphological aspects are often not sufficient to distinguish between them in routine diagnosis. Numerous cases do not frankly exhibit all criteria of each entity and/or exhibit characteristics belonging to other MZL categories such as engagement into plasma cell differentiation. The presence of splenomegaly and/or bone marrow infiltration can confuse the differential diagnosis between SMZLs, NMZLs and WM/LPLs. In particular, WHO 2008 criteria for NMZL diagnosis may result in the exclusion of cases with splenomegaly, and/or extranodal infiltration. Compared with other MZLs, no specific cytogenetic abnormalities or genomic DNA copy numbers have been identified at present for NMZLs. Considering the unbalanced genomic lesions, NZMLs are intermediate between SMZLs and MALT lymphomas. 9 Despite a recent publication that reports results of high-throughput analysis of these tumors, highlighting variations in the expression of interleukins, integrins, CD40, phosphatidylinositol 3-kinase, nuclear factor-kB (NF-kB) and transforming growth factor-b pathways, 10 NMZLs still lack specific markers today.
Because the maturation history of a B-cell is physiologically imprinted on the immunoglobulin (IG) gene sequence, analysis of immunoglobulin heavy chain variable (IGHV) sequences of clonal tumor cells provides information on cell origin and antigen dependence. For example, MALT lymphomas are characterized by overrepresentation of IGHV gene rearrangement with CDR3 features of autoreactivity. 11 Looking at the IGHV sequences, we previously reported that SMZLs and WM/LPLs show different antigen exposure histories. 12 We and others found that SMZLs are characterized by an overrepresentation of the IGHV1-2 gene, with a low level of IGHV somatic mutation, no antigenic selection pressure and with long CDR3 amino-acid sequences. 13, 14 These features suggested a history of chronic antigen stimulation with autoreactivity and without evidence for a germinal center passage. In SMZL, cases with IGHV1-2 gene rearrangement are characterized by a complex canonical motif, 13 14 demonstrated that IGHV1-2 antibodies are often polyreactive and react against selfantigens, arguing in favor of a marginal zone IgM þ memory B-cell origin of SMZLs. The WM/LPL IGHV gene repertoire is completely different from that of SMZLs as it is characterized by an overrepresentation of IGHV3-23 genes with high IGHV mutation rates, strong data supporting antigenic selection pressure and short CDR3 segments. 12, 16 These features indicate that WM/LPL tumor B cells are of a postgerminal center B-cell origin, having been submitted to T-dependant antigen selection. [17] [18] [19] Thus, MALT lymphomas, SMZLs and WM/LPLs exhibit significant and markedly different IGHV gene repertoires and characteristics, fully agreeing with the fact that these lymphomas correspond to three different entities. These studies demonstrate the relevance of extensive analysis of IGHV sequences in understanding the physiopathology of MZLs. Recently, it has been reported that WM/LPLs are specifically associated with mutation of the MYD88 gene, consolidating the existence of this entity from a molecular point of view. 20, 21 The aim of this study was to analyze IGHV gene sequences from MZLs. Additionally, as (1) MYD88 mutations are likely to be important in NF-kB-related B-cell lymphomagenesis including WM/LPLs, [20] [21] [22] (2) constitutive NF-kB activation is recurrently questioned in MZLs and (3) some cases of SMZLs with MYD88 mutations have been reported, 23 we looked for the MYD88 L265P mutation, first described in diffuse large B-cell lymphomas and responsible for constitutive activation of NF-kB. 22 
MATERIALS AND METHODS
Patients, specimen biopsies, labeling and classification A retrospective series of 168 patients with either an initial diagnosis of MZL or WM/LPL was initially selected. In addition to histopathological study of the tumor, clinical course, physical examination, bone marrow biopsy, biological parameters (lactate dehydrogenase, b2-microglobulin, serum protein profile, immunoglobulin peak levels), chest radiographs and computed tomography scans of the thorax, abdomen and pelvis were analyzed in order to diagnose these cases according to the WH0 2008 classification. Histopathological review of cases was done independantly by three pathologists (MP, IS and BP). A total of 123 patients with complete clinical, biological and histopathological information were then reclassified. Bone marrow infiltration was diagnosed either by histopathological examination of the biopsy (117 cases) or by cytology and flow cytometry (6 cases). SMZL, NMZL or MALT lymphomas were diagnosed for 53, 11 and 28 patients, respectively. WM/LPL was diagnosed for 31 cases. Interestingly, all reclassified cases (16 patients) were before 2008 and were initially diagnosed as NMZL because of the lymph node infiltration. These cases were reclassified as WM/LPL (12 cases), MALT lymphoma (3 cases) and SMZL (1 case).
DNA extraction and sequencing of IGHV gene sequences Genomic DNA was extracted by a standard phenol chloroform procedure. Immunoglobulin heavy chain VDJ locus was amplified in duplicate using the Biomed-2 strategy 24 with FR1 and FR2 primers as previously described. 12 After excision of monoclonal VDJ rearranged fragments from 2% low melting agarose gels and purification with Qiaquick spin columns (Qiagen GmbH, Hilden, Germany) following the manufacturer's recommendations, the PCR products were directly sequenced on both strands with the same primers using Sanger's chain-termination method and fluorescent dideoxynucleotides. 25 Sequencing was performed with the ABI Prism Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and reaction products were analyzed on an automatic 3100 DNA sequencer (Applied Biosystems) using ABI Prism sequencing Analysis 3.7 software.
Analysis of IGHV sequences
The clonal DNA IGHV sequence of the tumor was aligned with the closest germline sequence using three immunoglobulin sequence data base dedicated sites: international ImMunoGeneTics databases, 26 VBASE director 27 (http://vbase.mrc-cpe.cam.ac.uk/) and IgBLAST database (http:// www.ncbi.nlm.nih.gov/igblast/). All cases were potentially functional without stop codons and with VDJ rearrangements in the correct reading frame. Misalignments were not due to Taq polymerase, as direct sequencing of PCR products was performed. Sequences were translated into amino acids in order to identify the functional IGHV gene rearrangement. The percentage of homology between the functional IGHV segment used in the tumor and the germline sequence was then calculated (excluding primer sequences). The mutation percentage was arbitrarily given as 100 minus the percentage of homology. The number of silent (S) and replacing (R) mutations was calculated by comparing the amino-acid sequence of each V domain with its germline IGHV sequence. The length of CDR3 regions was determined according to IGMT numbering (http://www.imgt.org/IMGT_vquest/vquest?livret=0&Option=humanIg).
Statistical analysis of the distribution of IGHV somatic mutations between FR and CDR segments
Analysis of antigen selection was performed using the multinomial model described by Lossos et al. 28 We developed an algorithm to automatically compute and simultaneously analyze several sequences.
12 CDR3 segments and substitutions resulting in stop codons were excluded from the calculation as recommended. 29 By counting substitutions resulting in an amino-acid replacement or not (R and S mutations, respectively), Rf and P-values for R and S mutations could be calculated. Student's t-test and nonparametric Mann-Whitney test were performed with Statview software (SAS Institute Inc., Cary, NC, USA).
Screening for MYD88 L265P mutations
MYD88 L265P mutations were identified after genomic DNA amplification of the MYD88 exon 5 (5 0 primer: 5 0 -CTTAGATGGGGGATGGCTGT-3 0 ; 3 0 primer: 5 0 -AGGAGGCAGGGCAGAAGTA-3 0 ) and digestion of the PCR product with BsiE1 (restriction site:
. The amplification product from mutated MYD88 L265P was thus cut into two fragments by the enzyme when the mutation was present (Figure 1 ). The presence of the MYD88 L265P mutation was then confirmed by direct sequencing of the PCR product.
RESULTS

Clinicopathologic features
The aim of this study was to examine the IGHV sequences and MYD88 mutations on a large series of different types of MZLs and WM/LPL in order to identify specific features for these entities ( MZLs of lymph nodes (primary lymph node tumors displaying a parafollicular/perisinusoidal distribution of neoplastic cells or a nodular pattern, and composed of an admixture of centrocyte-like cells, monocytoid cells, scattered blasts and small cells with or without plasmacytoid differentiation but without immunoglobulin peak) were divided in two series: 7 corresponded to localized lymph node enlargement without splenomegaly, immunoglobulin peak or extranodal infiltration. Four cases were disseminated with spleen enlargement and/or bone marrow infiltration but without any immunoglobulin peak. These four cases had a natural history corresponding to primary lymph node infiltration years before secondary dissemination to spleen and/or bone marrow. Even if numbers are small, bone marrow infiltration was not intrasinusoidal and was rather nodular. Thus, a genuine diagnosis of NMZL could be made for 11 cases, 4 of them with secondary dissemination.
MALT lymphomas were defined by primary extranodal infiltration of a MZL: 8/28 (29%) were from the gastrointestinal tract, 7/28 (25%) from ocular annexes, 7/28 (25%) from lung, 5/28 (18%) from the ENT sphere and 1/28 (4%) from the skin. Out of 28 cases, 13 (46%) were disseminated, either to the bone marrow (11%) or lymph nodes (46%).
A diagnosis of WM/LPL was made for 31 cases when bone marrow infiltration by a LPL with an IgM peak was found. Tumor infiltration was composed of small lymphocytes with a variable degree of plasma cell maturation plus or minus mast cell expansion. Infiltration pattern was interstitial (68%, 33% of them with isolated interstitial pattern), nodular (48%), diffuse (13%) or intrasinusoidal (3%). Sole bone marrow infiltration was found in 14/31 (45%) cases and dissemination to lymph nodes and/or spleen in 17/31 cases (55%).
IGHV mutation analysis
To search for specific features of each entity, the first step was to globally analyze the IGHV repertoire and characteristics of the Regarding NMZLs, IGHV1 and IGHV3 gene rearrangements were found in 27% (all IGHV1-2) and 55% (27% being IGHV3-23) of cases, respectively. IGHV mutation rates were over 2% for 3/11 cases (27%, all with IGHV3 gene rearrangements). Absence of features of selection pressure and increased CDR3 length were found in 7/11 (64%) and 6/11 (55%) cases, respectively. The SMZLassociated IGHV1-2 canonical motif was not found in NMZL cases. No differences were seen between localized and disseminated NMZLs.
The IGHV gene repertoire of MALT lymphomas was characterized by a frequency of IGHV1, IGHV3 and IGHV4 gene rearrangements in 8/28 (29%, including 4 cases with a IGHV1-69 gene rearrangement), 13/28 (46%) and 5/28 (18%) cases, respectively. The IGHV mutation rate was over 2% in 23/28 cases (82%). Absence of selection pressure was found in 64% cases. CDR3 length exceeded 17 amino acids in 12/28 (43%) cases.
LPL/WM were characterized by an overrepresentation of IGHV3 gene rearrangements (24/31 ¼ 77%). Frequency of IGHV3-23 and IGHV3-7 genes was 11/24 (46%) and 7/24 (29%). Mutation rates were intermediate or high in all cases, 24/31 (77%) cases with a high mutation rate (45%). Features of selection pressure were found in 90% cases. CDR3 length was short in 27/31 cases (87%). No difference could be found between cases with or without dissemination outside the bone marrow.
MYD88 mutation analysis Since MYD88 has been reported to be mutated in nearly all WM/LPLs, 20 we next looked for MYD88 L265P mutations. This mutation was found in 22/118 (19%) cases of the whole series, corresponding to 2/53 SMZLs (4%), 0/11 NMZLs, 2/28 (7%) MALT lymphomas and 18/27 (67%) WM/LPL (Table 1 and Figure 1) . Again, no differences could be found between disseminated and localized NMZLs as well as between WM/LPLs with only bone marrow infiltration and those disseminated outside the bone marrow.
We next looked at the characteristics of patients with the MYD88 L265P mutation regardless of the histopathological diagnosis ( Figure 2 ). All cases with the MYD88 L265P mutation had an IgM peak and all but one MALT lymphoma had bone marrow infiltration (Figures 2a and b) . Cases with the MYD88 L265P mutation were characterized by an increased frequency of IGHV3 gene rearrangement (18/22 ¼ 82%). Reciprocally, 18/52 (35%) cases with an IGHV3 gene rearrangement had the MYD88 L265P mutation, with IGHV3-7 gene overrepresentation (Figure 2c ). Indeed, 6/10 (60%) cases with an IGHV3-7 gene rearrangement exhibited the MYD88 L265P mutation. Cases with the MYD88 L265P mutation were also characterized by high IGHV mutation rate, antigenic selection pressure and short CDR3 length (Figure 2d) .
We thus looked in detail at characteristics of the 11 cases with this IGHV3-7 gene rearrangement. This series included one SMZL, one NMZL, two MALT lymphomas and seven WM/LPLs. All but the NMZL case had a mutated IGHV gene. Features of selection pressure were found in 8/11 cases (73%) and CDR3 length was short (o17 amino acids) in 8/11 (73%) cases. Five out of six (83%) WM/LPL cases with IGHV3-7 gene rearrangements also had the MYD88 L265P mutation. Only one out of the four non-WM/LPL cases had the MYD88 L265P mutation. Thus, it seems that IGHV3-7 gene rearrangement was associated with an IGHV somatic mutation process but not with the MYD88 L265P mutation. In other words, in the context of the IGHV3-7 gene rearrangement, the MYD88 L265P mutation was strongly associated with WM/ LPLs.
DISCUSSION
During the 1990s, the concept of MZL was established. These tumors were rapidly separated into MALT lymphomas and non-MALT lymphomas including SMZLs and NMZLs. 4 SMZLs were also rather rapidly recognized as original entities. 32 Now, the current 2008 WHO classification recognizes both SMZLs and WM/LPLs as well-separated clinicopathologic entities, the latter being characterized by an IgM peak due to a monoclonal expansion of predominantly small B lymphocytes with variable plasmacytoid differentiation and primary bone marrow infiltration. 5 The question of proximity between NMZLs and WM/LPLs has been raised by various authors. 3, 33, 34 In this retrospective series, we analyzed 168 patients with a diagnosis suspicion of MZL or WM/LPL, most of them being classified according to the WHO 2001 lymphoma classification. Only 123 patients could be classified according to the WHO 2008 because of the lack of clinical or biological data, which stress their importance for correct diagnosis. SMZLs and WM/LPLs emerged clearly from this IGHV analysis. In agreement with Bikos et al. 15 and Zibellini et al., 13 SMZLs were characterized by an overrepresentation of IGHV1-2 gene rearrangements with a canonical motif, low or intermediate mutation rates, without selection pressure and with long CDR3 segments. These features contrasted with those of WM/LPL, which were associated with an IGHV3-23 overrepresentation, high IGHV mutation rates, features of selection pressure and short CDR3 segments, as published by us and others.
One key difference between the WHO 2001 and 2008 classifications resides in the diagnosis of WM/LPLs and NMZLs. In the previous 2001 WHO classification of lymphomas, it was suggested that the monoclonal IgM peak would only be a clinical symptom shared by MZLs and LPLs and that genuine LPLs would be exceedingly rare. 35 Now, the current 2008 WHO classification recognizes the existence of WM/LPLs as a well-separated clinicopathologic entity, being characterized by an IgM peak due to a monoclonal expansion of predominantly small B lymphocytes with variable plasmacytoid differentiation and primary bone marrow infiltration. 5 The MYD88 L265P mutation is not the sole MYD88 mutation reported in B-cell lymphomas, 22 and to find WM/ LPL cases without this mutation does not eliminate a genetic alteration of the MYD88 gene. But, to find that the MYD88 L265P mutation was almost exclusively restricted to WM/LPL very strongly argues in favor of the WHO 2008 classification for WM/ LPLs. It is of importance to note that, according to the WHO 2001 classification, most patients with lymph node and bone marrow infiltration and an immunoglobulin peak were initially diagnosed as NMZL with bone marrow infiltration. Yet, there was absolutely no difference between WM/LPL patients with only bone marrow infiltration and with tumor dissemination to lymph nodes in terms of IGHV profile and frequency of MYD88 L265P mutations. This clearly suggests that, regardless of tumor dissemination status, patients with bone marrow infiltration by a LPL and IgM peak belong to the same group of tumors, WM/LPL. On its own, the MYD88 L265P mutation is above all associated with an IgM peak. Our data are thus very strongly in favor of the original intuition of Jan Gö sta Waldenströ m, 36 who suggested that patients with an
IgM peak (so-called 'hyperviscosity syndrome' at these times) belong to the same disease group. Even if not completely specific, morphology is still very important as almost all SMZL patients had bone marrow dissemination and 26% had an IgM peak. And indeed, we previously demonstrated that bone marrow morphological analysis discriminated accurately between SMZLs and WM/LPLs. 12 In this series, it was found that SMZL infiltration of bone marrow was rather intrasinusoidal and/or nodular, whereas WM/LPL infiltration was rather interstitial. To find such a high frequency and restriction of MYD88 L265P in and to WM/LPLs also suggests that, like myeloma, NF-kB constitutive activation would be an important physiopathological event in the emergence of clonal populations. This would explain why new therapies targeting NF-kB activation such as Bortezomib could be effective in this disease. 37 Two SMZLs and two MALT lymphomas (ocular annexes localization) with MYD88 L265P mutation were also found. Of note, the detection of MYD88 L265P mutation has been done from DNA extracted from the tumor biopsy. Histopathological rereading of the tumor biopsy confirmed the diagnosis of MZL. Like others with the MYD88 L265P mutation, these four cases exhibited an IgM peak. One of the two MALT lymphomas had no detectable bone marrow infiltration. For the three remaining cases, the initial cause of the first medical advice was the discovery of an IgM peak for the MALT lymphoma and of increased lymphocytosis for the two SMZLs. Bone marrow biopsies were not done, but concomitant bone marrow smears were performed at the time of the diagnosis for these three remaining cases (two SMZLs and one MALT lymphoma). These three cases were all associated with cytological features of plasmacytic differentiation at various degrees, with an aspect closed to those found in WM/LPL, one SMZL case with noticeable mast cell expansion. Therefore, even if histology of the tumor biopsy were in favor of a MZL, the question of the differential diagnosis with WM/LPL is clearly raised from the bone marrow point of view for these three cases, with a compatible clinical course. Thus, these three cases clearly raise the question of the accuracy of current diagnosis criteria for WM/ LPL diagnosis. It can be put forward that detection of genetic alterations of MYD88 gene will lead to refine WM/LPL diagnosis criteria of this entity.
Little information is available about NMZL IGHV profile. The largest series published by Traverse-Glehen et al.
38 included 14 cases. Analysis of IGHV gene rearrangement suggested that SMZLs would have an antigenic exposure history different from that of NMZLs, the latter being rather heterogeneous but with a IGHV4-34 predominance. The second largest published series of 10 cases (Marasca et al. 39 ) mixed patients with and without infection by HCV (five cases each). This paper reported an increased frequency of IGHV4-34 and IGHV1-69 clonal rearrangements in both HCV-and non-HCV-infected patients. 39 Camacho et al. 40 reported a short series of five NMZLs and found an IGHV3 gene rearrangement in 4/5 cases. Thus, it is difficult to conclude from the literature whether NMZLs have a homogenous antigen exposure history like SMZLs or WM/LPLs. In fact, the main difficulty for NMZLs is the differential diagnosis between other MZLs (SMZLs or MALTs) and WM/LPLs. The WHO 2008 classification recommends making a diagnosis of NMZL only for cases without evidence of extranodal and/or spleen infiltration. Bone marrow dissemination raises the question of differential diagnosis with WM/LPLs. In contrast to with WM/LPLs, an absence of IgM peak seems to be a cardinal feature of NMZLs. Like WM/ LPL, NMZLs were characterized by increased frequencies of IGHV3 genes. But the IGHV mutation rate was low for most cases, often with absence of selection pressure and long CDR3 segments. It is important to note that this IGHV profile was similar between patients with localized or disseminated tumors. The absence of MYD88 L265P mutations in patients with a diagnosis of disseminated NMZL (with a bone marrow infiltration but without immunoglobulin peak) strongly suggests that the biology of NMZLs and WM/LPLs is different. The NMZL IGHV profile is also clearly different from that of SMZLs, arguing in favor of a different antigen exposure history. The IGHV repertoire of NMZLs is closer to that of MALT lymphomas than to SMZLs or WM/LPLs. But the frequency of patients with mutated IGHV gene rearrangements is very different between NMZLs and MALT lymphomas. Thus, again, by using the WHO 2008 criteria for diagnosis of NMZLs, we identified a rather homogeneous group in terms of IGHV characteristics that were different from WM/LPLs and SMZLs. Physiologically, naive B cells bearing IGHV gene rearrangements close to those of NMZLs, that is, unmutated IGHV genes with long CDR3 segments, have been reported by various groups. 41, 42 These B cells would express polyreactive immunoglobulins responsible for self-reactivity and production of natural antibodies.
In conclusion, analysis of this series with a firm diagnosis of MZLs or WM/LPLs according to the 2008 WHO classification demonstrated that antigen exposure history of these four entities is different and that MYD88 L265P is specifically associated with WM/LPLs. Therefore, these four entities are very likely to undergo specific primary oncogenic pathways at the time of transformation.
